In the setting of follicular lymphoma (FL), frontline therapy with rituximab, cyclophosphamide,
doxorubicin, and prednisone (R-CHOP) has represented for many years the standard of …

Background Rituximab plus bendamustine (R‐B) has been demonstrated to improve
outcomes and reduce toxicity compared with rituximab, cyclophosphamide, doxorubicin, and …

Based on centroblast frequency, follicular lymphoma (FL) is subdivided into grades 1-2, 3A,
and 3B. Grade FL3A frequently coexists with FL1-2 (FL1-2-3A). Based on clinical trials, FL1 …

We conducted a post hoc analysis of the FOLL12 trial to determine the impact of different
initial immunochemotherapy (ICT) regimens on patient outcomes. Patients were selected …

Background: Bendamustine and rituximab (BR) is a commonly chosen frontline treatment for
grade 1-2 (G 1-2) follicular lymphoma (FL). This regimen resulted in significantly longer …

e19552 Background: Bendamustine-rituximab (BR) is the preferred regimen for treatment
naïve follicular lymphoma (FL). Lenalidomide-rituximab (LR), a chemotherapy-free protocol …

The aim of this trial is to evaluate the utility of rituximab–bendamustine (R–B) for untreated
advanced follicular lymphoma (FL) showing non-optimal response (nOR) to R-CHOP, and to …

Introduction Bendamustine-rituximab (BR) has exhibited improved outcomes as a first-line
therapy for follicular lymphoma (FL). Nevertheless, concerns regarding secondary …

Background: Bendamustine and rituximab (BR) has been a preferred regimen for frontline
therapy of patients (pts) with advanced stage follicular lymphoma (FL) since randomized …

Background Few studies have evaluated real-world treatment patterns and survival in
follicular lymphoma (FL). This study evaluated these outcomes among newly diagnosed …